ACADIA Pharmaceuticals Inc (ACAD)
Receivables turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 957,797 | 929,236 | 890,534 | 813,806 | 726,437 | 631,886 | 550,901 | 520,229 | 517,235 | 511,503 | 512,401 | 493,059 | 484,145 | 474,394 | 463,359 | 458,241 | 441,755 | 419,074 | 393,083 | 366,185 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $957,797K ÷ $—K
= —
Based on the provided data, the receivables turnover ratio for ACADIA Pharmaceuticals Inc is not available for any of the reporting periods up to December 31, 2024. This indicates that the company's financial statements do not disclose the necessary information to calculate the receivables turnover ratio, which is a key indicator of how efficiently the company is collecting outstanding receivables from its customers.
The receivables turnover ratio is typically calculated by dividing net credit sales by the average accounts receivable balance during a specific period. A higher receivables turnover ratio generally indicates that a company is more efficient in collecting payments from customers, while a lower ratio may suggest potential issues with collecting outstanding receivables.
Without access to the receivables turnover ratio data for ACADIA Pharmaceuticals Inc, it is challenging to assess the company's effectiveness in managing its accounts receivable and collecting payments on time. Investors and analysts often use this ratio to evaluate a company's liquidity, operational efficiency, and overall financial health. It is recommended for the company to provide more transparent and detailed financial information in its future disclosures to facilitate a more thorough analysis of its financial performance.
Peer comparison
Dec 31, 2024